Monitoring the ACTIVE-W trial: Some issues in monitoring a noninferiority trial

American Heart Journal

Volumn 155, Issue 1, 2008, Pages 33-41

  Cairns, John A ^a   Wittes, Janet ^b   Wyse, D George ^c   Pogue, Janet ^d   Gent, Michael ^d   Hirsh, Jack ^d   Marler, John ^e   Pritchett, Edward L C ^f  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b University of Iowa   (United States)

^c LIBIN CARDIOVASCULAR INSTITUTE OF ALBERTA   (Canada)

^d MCMASTER UNIVERSITY   (Canada)

^e NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^f DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; IRBESARTAN; PLACEBO;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; META ANALYSIS; MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; BIPHENYL COMPOUNDS; CLINICAL TRIALS DATA MONITORING COMMITTEES; DECISION MAKING; FEMALE; HUMANS; MALE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TETRAZOLES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 36849062291     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.09.011     Document Type: Article

References (18)

1. ACTIVE Writing Group on behalf of the ACTIVE Investigators, Connolly S., Pogue J., Hart R., et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet 367 (2006) 1903-1912
2. Wittes J. Active-control trials-a linguistic problem. Int Chin Stat Soc Bull (2001) 39-40
3. D'Agostino R.B., Massaro J.M., and Sullivan L.M. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat Med 22 (2003) 169-186
4. Lange S., and Freitag G. Choice of delta: requirements and reality-results of a systematic review. Biometrical J 1 (2005) 12-27
5. Piaggio G., Elbourne D.R., Altman D.G., et al., for the CONSORT Group. Reporting of noninferiority and equivalence randomized trials. An extension of the CONSORT Statement. JAMA 295 (2006) 1152-1160
6. Kaul S., Diamond G.A., and Weintraub W.S. Trials and tribulations of non-inferiority. The ximelagatran experience. J Am Coll Cardiol 46 (2005) 1986-1995
7. Kaul S., and Diamond G.A. Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials. Progr Cardiovasc Dis 49 (2007) 284-299
8. Echt D.S., Liebson P.R., Mitchell L.B., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324 (1991) 781-788
9. DeMets D.L., and Friedman L.M. The data monitoring experience in the Cardiac Arrhythmia Suppression Trial: the need to be prepared early. In: DeMets D.L., Furberg C.D., and Friedman L.M. (Eds). Data monitoring in clinical trials (2006), Springer, New York (NY) 198-208
10. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
11. Lan K.K., Simon R., and Halperin M. Stochastically curtailed sampling in long-term clinical trials. Commun Stat Theory Methods 13 (1984) 2339-2353
12. Lan K.K., and Wittes J. The B-value: a tool for monitoring data. Biometrics 44 (1988) 579-585
13. Ware J.H., Muller J.E., and Braunwald E. The futility index. An approach to the cost-effective termination of randomized clinical trials. Am J Med 78 (1985) 635-643
14. Lachin J.M. A review of methods for futility stopping based on conditional power. Statis Med 24 (2005) 2747-2764
15. Freemantle N., Calvert M., Wood J., et al. Composite outcomes in randomized trials. Greater precision but with greater uncertainty?. JAMA 289 (2003) 2554-2559
16. Montori V.M., Permanyer-Miralda, Ferreira-Gonzalez, et al. Validity of composite end points in clinical trials. BMJ 330 (2005) 594-596
17. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355 (2006) 2203-2216
18. Pocock S.J. Current controversies in data monitoring for clinical trials. Clin Trials 3 (2006) 513-521